Research monograph · growth hormone-releasing hormone (ghrh) analog; n-terminal 29-amino-acid fragment of human ghrh
GH Secretion Studies
This monograph collects what the published literature reports about Sermorelin — its mechanisms, the areas it is studied in, its molecular record and the sources behind them. Because it acts upstream and preserves the pituitary's own feedback control, research using it examines endogenous release patterns rather than exogenous replacement.
For laboratory research use only — not for human or animal use
Mechanisms
GHRH Receptor Agonism
The 29-residue N-terminal fragment is the shortest portion of GHRH that retains full activity at the receptor. Everything beyond residue 29 turns out to be dispensable for binding.
Downstream IGF-1 Signaling
Growth hormone released in response drives hepatic IGF-1 production, so IGF-1 is measured as a downstream marker rather than as a direct effect of the peptide.
Preserved Physiologic Rhythm
Because it acts on the pituitary rather than bypassing it, somatostatin feedback stays intact and release follows the body's own rhythm. That preservation is the methodological argument for using it.
Stimulates, Not Replaces
The distinction matters for study design: this is a secretagogue acting upstream, not exogenous growth hormone, so endpoints reflect what the pituitary does rather than what was administered.
Studied applications
Acting upstream leaves pituitary feedback intact, so what is measured is the axis behaving rather than a hormone administered.
GHRH stimulation literature
Body composition is measured as a downstream consequence of altered release, not as a direct effect of the peptide.
Body-composition research
Endogenous release peaks in slow-wave sleep, so sleep architecture is both a variable and an endpoint here.
Sleep-axis research
Age-related decline in the axis is the premise, and this compound is used to test whether upstream stimulation still produces a response.
Aging-axis research
What the published work measures
The endpoints reported across the literature for this compound. The figures belong to the individual papers, not to us.
Reference values
Scroll for full molecular data →
| Sequence | N-terminal 29-amino-acid fragment of human GHRH |
|---|---|
| Molecular weight | 3,357.93 g/mol |
| Physical form | Lyophilized powder |
| Documented purity | Quantified by HPLC, reported per lot |
| Storage | -20°C for long-term stability |
| Solubility | Water-soluble |
| Available sizes | 10mg |
FAQ
Sermorelin is the 29-residue N-terminal fragment of GHRH — the shortest portion of the hormone that retains full biological activity at the GHRH receptor. Because it acts upstream and preserves the pituitary's own feedback control, research using it examines endogenous release patterns rather than exogenous replacement.
Published research on Sermorelin concentrates on Growth Hormone Axis, Lean Mass & Adiposity, Slow-Wave Sleep and Somatopause. Each of those areas is summarised further up this page with the citation it comes from, and the full reference list — 3 indexed publications — sits at the bottom. Study designs and concentrations vary considerably between publications, so the primary sources are worth reading directly.
The literature describes Sermorelin acting across GHRH Receptor Agonism, Downstream IGF-1 Signaling, Preserved Physiologic Rhythm and Stimulates, Not Replaces, reported respectively as GHRH-R, GH → IGF-1, Feedback and Upstream. Those pathways are drawn from preclinical models rather than clinical work, and they describe what has been observed rather than a settled mechanism — the individual pathway cards above cite what each one is based on.
Sermorelin has a molecular formula of C149H246N44O42S, an average mass of 3357.93 g/mol and the sequence N-terminal 29-amino-acid fragment of human GHRH. It is indexed under CAS 86168-78-7. It ships as lyophilized powder. Those are nominal reference values for the parent compound. The identity of the specific material you receive is confirmed by mass spectrometry and reported on that lot's certificate.
Store the sealed vial at -20°C, protected from light and moisture, and let it reach room temperature before opening so condensation does not form on cold powder. Sermorelin is water-soluble; reconstitute by directing the diluent down the vial wall rather than onto the powder, then swirl to dissolve rather than shaking. Keep reconstituted solution refrigerated and avoid repeated freeze-thaw cycles — solutions are far less stable than lyophilized powder.
No. Sermorelin is supplied strictly for in-vitro laboratory research and development. It is not a drug, food, supplement or cosmetic, it has not been evaluated by the FDA, and it is not intended for human or animal consumption, ingestion, injection or any in-vivo use. Ordering confirms you are a qualified researcher or institution purchasing on that basis.
Cited sources
Independent published research indexed from PubMed — not Routine Peptides claims.
Before you order
Every production run is analyzed by an independent laboratory, and the certificate for your lot travels with the order — not a catalog-wide document, and not a summary written by us.
